Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30007896HIVENSG00000138363.15protein_codingATICYesNo471P31939
TVIS30052334HIVENSG00000138363.15protein_codingATICYesNo471P31939
TVIS30052335HIVENSG00000138363.15protein_codingATICYesNo471P31939
TVIS44037937HTLV-1ENSG00000138363.15protein_codingATICYesNo471P31939
TVIS44037738HTLV-1ENSG00000138363.15protein_codingATICYesNo471P31939
TVIS44037936HTLV-1ENSG00000138363.15protein_codingATICYesNo471P31939
TVIS44044411HTLV-1ENSG00000138363.15protein_codingATICYesNo471P31939
TVIS44037935HTLV-1ENSG00000138363.15protein_codingATICYesNo471P31939
TCGA Plot Options
Drug Information
GeneATIC
DrugBank IDDB00642
Drug NamePemetrexed
Target IDBE0001240
UniProt IDP31939
Regulation Typeinhibitor
PubMed IDs12571811; 11524555; 19549896
CitationsKindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53.@@Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73.@@Racanelli AC, Rothbart SB, Heyer CL, Moran RG: Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009 Jul 1;69(13):5467-74. doi: 10.1158/0008-5472.CAN-08-4979. Epub 2009 Jun 23.
GroupsApproved; Investigational
Direct ClassificationGlutamic acid and derivatives
SMILESNC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
Pathways
PharmGKBPA10810
ChEMBLCHEMBL225072